ABBV vs PTGX
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. PTGX: Protagonist Therapeutics is a biopharmaceutical company developing novel peptide-based therapies to treat chronic diseases through internal research and strategic collaborations.
Side-by-side fundamentals
| Metric | ABBV | PTGX | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $246.04 | $145.87 | |
| Market cap as of 2026-08-10 | $434.7B | $9.4B | |
| P/E as of 2026-08-10 | 119.61 | 113.85 | PTGX lower |
| PEG as of 2026-08-10 | 6.59 | 3.10 | PTGX lower |
| Net margin as of 2026-08-10 | +5.8% | +29.4% | PTGX higher |
| Gross margin as of 2026-08-10 | +72.0% | n/a | |
| Operating margin as of 2026-08-10 | +24.4% | +20.7% | ABBV higher |
| ROE as of 2026-08-10 | +95.6% | +12.0% | ABBV higher |
| ROA as of 2026-08-10 | +2.7% | +11.2% | PTGX higher |
| Debt / equity as of 2026-08-10 | 49.22 | 0.00 | PTGX lower |
| Revenue growth (YoY) as of 2026-08-10 | +9.5% | +34.8% | PTGX higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | n/a | |
| Dividend yield as of 2026-08-10 | +2.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-10 | 0.21 | 1.49 | |
| 1-year return as of 2026-08-07 close | +23.7% | +186.2% | PTGX higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.